Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate ... sales this year from an ever-lengthening list of indications associated with type 2 ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio ... Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys.

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

“There is a huge demand for these drugs at the right price.” France’s Economy Minister Antoine Armand wants guarantees from Sanofi that production of its popular Doliprane painkiller will ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

In May, Sanofi set the strictest price increase caps. The company committed not to increase the list price of existing drugs in the US by more than the rate of healthcare inflation and also plans ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...